This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, M. Y.
Right arrow Articles by Hota, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, M. Y.
Right arrow Articles by Hota, B.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Antibiotics

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2008, p. 3188-3194, Vol. 52, No. 9
0066-4804/08/$08.00+0     doi:10.1128/AAC.01553-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Delay of Active Antimicrobial Therapy and Mortality among Patients with Bacteremia: Impact of Severe Neutropenia{triangledown}

Michael Y. Lin,1,2* Robert A. Weinstein,1,2 and Bala Hota1,2

Section of Infectious Diseases, Rush University Medical Center, Chicago, Illinois,1 Division of Infectious Diseases, John H. Stroger, Jr. (Cook County) Hospital, Chicago, Illinois2

Received 3 December 2007/ Returned for modification 26 March 2008/ Accepted 4 July 2008

Increasing bacterial antimicrobial resistance has prompted physicians to choose broad-spectrum antimicrobials in order to reduce the likelihood of inactive empirical therapy. However, for bacteremic patients already receiving supportive care, it is unclear whether delay of active antimicrobial therapy significantly impacts patient outcomes. We performed a retrospective cohort study of patients with monomicrobial bloodstream infections at a large urban hospital in the United States from 2001 to 2006. We assessed the impact of delay of active antimicrobial therapy on mortality by using multivariable logistic regression modeling with and without propensity score methodology. We evaluated 1,523 episodes of monomicrobial bacterial bloodstream infections at our institution. Nine hundred eighty-three bacteremic episodes (64.5%) were treated with an active antimicrobial agent within 24 h of the index blood culture; the remaining 540 episodes (35.5%) were considered to have delay of active antimicrobial therapy. In adjusted analysis, among patients in the non-intensive-care-unit setting with an absolute neutrophil count (ANC) of <100 cells/µl, delay was associated with increased mortality (odds ratio [OR], 18.0; 95% confidence interval [CI], 2.84 to 114.5; P < 0.01); among intensive-care-unit patients with an ANC of <100 cells/µl, the effect of delay on mortality was nearly significant (OR, 5.56; 95% CI, 0.85 to 36.3; P = 0.07). However, for patients who were nonneutropenic (ANC, >500 cells/µl) or had ANCs of 100 to 500 cells/µl, delay was not associated with increased mortality. While the delay of active antimicrobial therapy was not significantly associated with higher mortality for most patients in this cohort, patients with severe neutropenia appeared to be vulnerable.

* Corresponding author. Mailing address: Rush University Medical Center, Section of Infectious Diseases, 600 S. Paulina St., Suite 143, Chicago, IL 60612. Phone: (312) 942-5865. Fax: (312) 942-8200. E-mail: michael_lin{at}rush.edu

{triangledown} Published ahead of print on 14 July 2008.

Antimicrobial Agents and Chemotherapy, September 2008, p. 3188-3194, Vol. 52, No. 9
0066-4804/08/$08.00+0     doi:10.1128/AAC.01553-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»